Neratinib augments the lethality of [regorafenib + sildenafil]-Reference-Cited by-同舟云学术

Neratinib augments the lethality of [regorafenib + sildenafil]

Published:2018-09-10 Issue:4 Volume:234 Page:4874-4887
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J Cell Physiol

Author:

Booth Laurence¹,Roberts Jane L.¹,Rais Rumeesa¹,Cutler Richard E.²,Diala Irmina²,Lalani Alshad S.²,Hancock John F.³,Poklepovic Andrew⁴,Dent Paul¹^ORCID

Affiliation:

1. Departments of Biochemistry and Molecular Biology, Massey Cancer Center Virginia Commonwealth University Richmond Virginia

2. Puma Biotechnology Inc., Los Angeles, California University of Texas Health Science Center Houston Texas

3. Department of Integrative Biology and Pharmacology University of Texas Health Science Center Houston Texas

4. Medicine, Virginia Commonwealth University Richmond Virginia

Funder

Institut National Du Cancer

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcp.27276

Reference23 articles.

1. Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo

2. Phosphodiesterase 5 Inhibitors Enhance Chemotherapy Killing in Gastrointestinal/Genitourinary Cancer Cells

3. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

4. [pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells

5. PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma;Molecular Carcinogenesis;2024-06-05

2. cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment;Journal of Hematology & Oncology;2024-01-17

3. Autophagy as a therapeutic mechanism to kill drug-resistant cancer cells;Anti-Cancer Drugs;2023-10-16

4. Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells;Anti-Cancer Drugs;2023-08-31

5. Neratinib as a Potential Therapeutic for Mutant RAS and Osimertinib-Resistant Tumours;European Medical Journal;2022-09-20